CIK THERAPY: CYTOKINE-INDUCED
KILLER CELL THERAPY

Cytokine-induced killer (CIK) cell therapy is an adoptive immunotherapy in which a patient's own peripheral blood cells are collected, activated ex vivo over 2–3 weeks using IFN-gamma, anti-CD3 antibody, IL-1, and IL-2, and reinfused to kill cancer cells. First described at the German Cancer Research Centre (DKFZ) in the early 1990s, it has since been developed into the world's largest non-CAR adoptive cell therapy programme — overwhelmingly in China.

“CIK cells kill tumor cells without MHC restriction, so they work well against cancers that avoid being recognized by regular T cells.”

• What Makes CIK Cells Different

  Unlike conventional T-cells that require MHC-restricted antigen presentation, CIK cells kill tumour cells via the NKG2D receptor — recognising stress ligands upregulated on cancer cells. Tumours that evade the immune system by downregulating MHC remain vulnerable to CIK killing.

• Where CIK Fits in Cancer Immunotherapy

  CIK occupies a distinct position from CAR-T therapy. It is more accessible, does not require genetic modification, has no CRS risk, and its evidence base is predominantly in solid tumours — precisely where CAR-T has had the least success. CIK is most commonly used as an adjuvant alongside surgery, chemotherapy, or radiation.

CIK cells are a heterogeneous population of immune effectors, combining the specificity of T-cells with the broad killing range of NK cells. Their dominant anti-tumor effector population, CD3+CD56+ T-NK cells, co-expresses markers of both lineages and provides potent, antigen-independent cytotoxicity.

• The CIK Cell Population

  The ex vivo expansion produces three key populations: CD3+CD56+ T-NK cells (primary killers — the dominant effector subset), CD3+CD56- activated T-cells, and CD3-CD56+ NK cells. The CD3+CD56+ subset combines T-cell memory potential with NK-cell killing range.

• NKG2D: The Key Recognition Receptor

  NKG2D binds MIC-A, MIC-B, and ULBP stress ligands upregulated on cancer cells by oncogenic activation and DNA damage. This tumour-selective mechanism requires no prior antigen knowledge. CIK cells also kill via perforin/granzyme, Fas/FasL apoptotic signalling, and inflammatory cytokine secretion.

• In Vivo Persistence

  CD3+CD56+ CIK cells have been detected in patient peripheral blood weeks to months after infusion. This persistence — combined with multiple treatment cycles — provides sustained immune surveillance against residual cancer cells rather than a single acute response.

• Immune Escape Resistance

  Because CIK killing does not depend on MHC presentation, tumours that escape conventional T-cell immunity by downregulating MHC class I expression — a common cancer immune evasion strategy — remain fully susceptible to CIK cell killing via NKG2D and perforin mechanisms.

CIK manufacturing is technically feasible at any well-equipped cell therapy laboratory and follows a well-standardized protocol, one of its key practical advantages over more complex engineered cell therapies. CIK manufacturing in China is conducted at cell therapy laboratories operating within hospital-based or independent GMP-certified facilities for cell therapy manufacturing. The Chinese regulatory framework — under the National Medical Products Administration (NMPA) and its predecessor agencies — has evolved over time to require that cell therapies used in clinical treatment be manufactured under defined quality standards with documented quality control procedures. Major cancer centers with active CIK programs, including the PLA General Hospital (301 Hospital), the Affiliated Hospital of the Chinese People's Liberation Army's Academy of Military Medical Sciences, and multiple academic cancer hospitals, operate dedicated cell therapy manufacturing units with established manufacturing protocols and quality systems. CancerFax works specifically with centers that operate under defined quality standards to ensure that patients receive a consistent, quality-controlled product.

1. 1

   Blood Collection and PBMC Isolation

   50–100 mL of the patient's venous blood is collected. Peripheral blood mononuclear cells (PBMCs) are isolated by density gradient centrifugation. Collection timing is coordinated with the treatment plan — typically before the nadir period of chemotherapy.

2. 2

   Ex Vivo Cytokine Stimulation (Day 0–1)

   Day 0: IFN-gamma (1000 IU/mL) initiates T-cell activation. Day 1: anti-CD3 monoclonal antibody, IL-1 beta, and IL-2 are added. Anti-CD3 provides the primary TCR activation signal; IL-2 drives proliferation and is replenished every 2–3 days throughout culture.

3. 3

   Cell Expansion (Days 2–21)

   Cells are expanded in culture flasks or bioreactor bags for 14–21 days. The CD3+CD56+ CIK population expands several hundred-fold from the starting PBMC number. The resulting product is a heterogeneous effector population with potent broad-spectrum anti-tumour cytotoxicity.

4. 4

   Quality Control and Release Testing

   Before reinfusion, the product undergoes flow cytometry (CD3+CD56+ phenotype confirmation), viability testing (minimum ≥80–85% viable cells required), and sterility testing (bacterial, fungal, mycoplasma). At GMP-certified Chinese centres, all steps are mandatory before patient release.

CIK therapy has the largest published clinical evidence base of any non-CAR adoptive cell therapy, derived predominantly from Chinese academic cancer centres.

• 2,000+Published StudiesOver 2,000 peer-reviewed publications on CIK therapy — more than any other non-CAR adoptive cell therapy globally.
• 82RCTs in Meta-AnalysisA Cancer Letters meta-analysis pooled 82 randomised controlled trials and 7,000+ patients, showing significant improvements in ORR, OS, and QoL across NSCLC, HCC, gastric, and CRC.
• 18% vs 46%HCC Recurrence Rate (CIK vs Control)Landmark RCT by Weng et al. (JCO 2008): adjuvant CIK after curative HCC surgery reduced 3-year recurrence from 45.5% to 18.3%.
• USD 8K–25KFull Course Cost in China4–6 cycles of CIK therapy at a major Chinese cancer centre — compared with USD 80,000–500,000 for CAR-T and USD 2,000–10,000 per cycle for imported checkpoint inhibitors.
• 0.59Pooled Hazard Ratio for Overall SurvivalA meta-analysis of adjuvant CIK after curative treatment for HCC found a pooled overall survival hazard ratio of 0.594, suggesting a meaningful survival benefit versus control.
• 7,000+Patients pooled in randomized evidenceThe Cancer Letters meta-analysis combined data from more than 7,000 patients across 82 randomized controlled trials, underlining how unusually large the CIK literature is for a non-CAR cell therapy.

CIK has been evaluated across virtually every major solid tumour type. Evidence strength and the consistency of clinical signal vary by cancer type.

Combining dendritic cell (DC) therapy with CIK therapy — known as DC-CIK — is one of the most commonly used immunotherapy protocols at Chinese cancer centres. It addresses the complementary weaknesses of each modality: DCs present tumour antigens but cannot kill; CIK cells kill broadly but without tumour-specific targeting.

• What Dendritic Cells Contribute

  DCs are the immune system's antigen-presenting cells — they capture tumour antigens, process them into peptides, and instruct T-cells on what to target. In cancer patients, DC function is frequently impaired by tumour-derived immunosuppressive factors. Ex vivo maturation restores DC function. When co-cultured with CIK cells before infusion, DCs present tumour antigens directly to CIK cells — giving the otherwise antigen-independent CIK population tumour-specific memory.

• Why the Combination Is More Potent

  DC co-culture during CIK manufacturing produces higher proportions of tumour-specific T-cells and greater NK-T cell cytotoxicity compared with CIK alone. A prospective RCT in advanced NSCLC showed significantly improved PFS and OS with DC-CIK plus chemotherapy vs chemotherapy alone. In HCC, DC-CIK showed superior DFS vs CIK alone in a comparative study.

• Manufacturing DC-CIK

  DC manufacturing runs in parallel with CIK expansion: blood monocytes are differentiated into DCs using GM-CSF + IL-4, then matured with tumour lysate or defined tumour peptides. The mature, tumour-antigen-loaded DCs are co-cultured with the expanding CIK cells for 24–48 hours before infusion, enabling bidirectional activation of both populations.

CIK is rarely used as a standalone treatment in contemporary Chinese practice. Synergistic mechanisms with standard cancer treatments are well-characterised and form the basis of most clinical protocols.

• CIK + Chemotherapy

  Chemotherapy kills tumour cells and releases antigens — creating an environment where CIK cells can recognise and respond. Low-dose cyclophosphamide and gemcitabine deplete immunosuppressive regulatory T-cells. CIK recipients report less fatigue and nausea during chemotherapy, possibly through immune-mediated normal tissue protection.

• CIK + Targeted Therapy

  EGFR inhibitors reduce VEGF production (which suppresses NK function) and may upregulate NKG2D ligands on cancer cells. VEGF TKIs in RCC and HCC reduce VEGF-mediated immunosuppression. Sorafenib + CIK in HCC has been evaluated in prospective trials with improved survival vs sorafenib alone.

• CIK + Radiation

  Radiation produces immunogenic cell death — releasing tumour antigens and creating an inflammatory microenvironment that activates reinfused CIK cells against those antigens, potentially enhancing the abscopal immune response. CIK is frequently given after concurrent chemoradiation in Chinese clinical practice.

• CIK + Surgery (Adjuvant)

  The post-surgical period — when primary tumour burden is eliminated but micrometastatic disease may remain — is conceptually the ideal window for CIK immune surveillance. Adjuvant CIK after curative resection for HCC, gastric, and colorectal cancer has the strongest evidence, with reduced recurrence rates in multiple studies.

CIK and CAR-T are not competitors — they address different cancer types, different treatment settings, and different patient populations. Understanding the differences helps patients make informed decisions about which approach is relevant for them.

CIK therapy has a consistently favourable safety profile across the published literature. Understanding what occurs, how frequently, and what it does not cause helps patients prepare realistically.

CIK's favourable safety profile makes it accessible to a broader range of patients than more intensive cell therapies. Appropriate selection still matters for maximising benefit.

• Strongest Candidates

  Post-curative surgery for HCC, gastric, colorectal, or lung cancer — adjuvant CIK to reduce recurrence. Patients receiving platinum-based chemotherapy for NSCLC, gastric, or oesophageal cancer — to enhance immune response. After completion of chemoradiation for NPC or locally advanced NSCLC. Combination with TACE or ablation for HCC.

• Maintenance Candidates

  Between chemotherapy cycles in advanced solid tumours to sustain immune surveillance. Patients who have completed all standard treatment options and seek a well-evidenced immune support approach. ECOG PS 0–2 required; adequate white cell counts for PBMC collection needed.

• Less Appropriate or Contraindicated

  Active severe autoimmune disease (may exacerbate). Active organ transplant with immunosuppression. Active uncontrolled infection. Very poor performance status (ECOG PS 4). Haematological malignancies — CIK has no established evidence base in leukaemias and lymphomas where CAR-T has superior evidence.

• Assessment Before Approval

  CancerFax conducts a thorough clinical assessment before recommending CIK — reviewing histology, molecular profile, stage, treatment history, and concurrent medications. We do not recommend CIK therapy to patients for whom it is unlikely to provide benefit or for whom it is contraindicated.

More patients have received CIK therapy in China than in all other countries combined. Chinese oncology institutions have generated the overwhelming majority of published clinical evidence in this field across more than three decades.

• Why China Became the Global Leader

  CIK gained traction in China during the 1990s and 2000s when Chinese centres were actively seeking complementary treatments for the high-burden cancer types dominant in China — HCC (world's highest burden), gastric cancer, NSCLC, and NPC. Relative manufacturing accessibility, early positive results from pioneering Chinese groups, and a regulatory environment that permitted CIK clinical use at accredited centres all drove development of the world's largest CIK programme.

• The Regulatory Framework

  Following a period in the mid-2010s when unregulated cell therapy at commercial clinics raised safety concerns, the NMPA implemented stricter oversight requiring CIK to be conducted within approved hospital settings under defined clinical protocols with ethics oversight, GMP manufacturing, and patient informed consent. CancerFax works exclusively with institutions operating under this framework.

• Leading Chinese CIK Centres

  PLA General Hospital (301 Hospital), Beijing — founding institution; landmark multi-tumour CIK studies. National Cancer Centre / Cancer Hospital CAMS, Beijing. Zhongshan Hospital Fudan University, Shanghai — HCC adjuvant CIK programmes. Sun Yat-sen University Cancer Centre, Guangzhou — NPC and hepatobiliary applications. West China Hospital Sichuan University, Chengdu. Multiple provincial cancer hospitals across Beijing, Shanghai, Guangzhou, Tianjin, Wuhan, and Hangzhou.

Each support page provides focused, in-depth coverage of a specific CIK therapy topic.

Frequently Asked Questions About CIK Therapy

Key questions from patients and families evaluating CIK therapy at Chinese cancer centres.